Search
Search Results
##search.searchResults.foundPlural##
-
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3714Suppl. Files: 1029PDF: 1015Html: 104 -
THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
3954PDF: 1856HTML: 1741 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
800PDF: 477HTML: 1282 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4689PDF: 1703HTML: 2685Untitled: 188 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3196PDF: 1305HTML: 2603 -
HEPATITIS C VIRUS INFECTION AND LYMPHOMA
919PDF: 510HTML: 7793 -
IMMUNE THROMBOCYTOPENIA ONSET AND RELAPSE DURING THE COVID19 PANDEMIC. A MONOCENTER STUDY. ITP and COVID19 infection and vaccination
1238PDF: 743HTML: 293 -
Refractory Immune Thrombocytopenic Purpura and Cytomegalovirus Infection: A Call for a Change in the Current Guidelines
4139PDF: 1120HTML: 2115Figure 1: 144 -
CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.
4115PDF: 1486HTML: 420 -
Tenofovir as Rescue Therapy Following Clinical Failure to Lamivudine in Severe Acute Hepatitis B
2057PDF: 768HTML: 1626Figure 1: 182 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2527PDF: 1027HTML: 95 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
2880PDF: 935HTML: 2049Cover letter: 159 -
Antivirals and monoclonal antibody combination therapy in haematological patients in the omicron era Antiviral and monoclonal Antibodies in Haematological Patients in the omicron era
1197PDF: 894HTML: 81 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1484PDF: 942HTML: 146 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1235PDF: 975HTML: 105 -
CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS. Anti-CMV immunoglobulins for CMV treatment
1844PDF: 1121HTML: 247 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
1941PDF: 1445HTML: 255 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
923PDF: 511HTML: 711 -
CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA
2502PDF: 1564HTML: 2333Table1: 172 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
3791PDF: 1049HTML: 407 -
Severe Acute Hepatitis B Treated with Entecavir
1437PDF: 733HTML: 2450Figure: 149Title page: 153disclosure: 91 -
LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE
1531PDF: 762HTML: 838jdoe, table 2 infections CML .doc: 170jdoe, table 1 infections CML .doc: 159 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1212PDF: 512HTML: 22989 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1340PDF: 707HTML: 189 -
FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator
2027PDF: 825HTML: 291 -
IMPLEMENTATION OF MICROELIMINATION STRATEGY IN ERADICATION OF CHRONIC HEPATITIS C INFECTION IN PATIENTS WITH HEMOPHILIA IN THE NORTHERN REGION OF SERBIA Microelimination Strategy of Chronic Hepatitis C Infection in patients with Hemophilia
794PDF: 306HTML: 137 -
-
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
1960PDF: 897HTML: 276







